Genedrive Plc

0.25 (1.41%)
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.25 1.41% 18.00 717,441 11:20:48
Bid Price Offer Price High Price Low Price Open Price
17.50 18.50 19.00 17.75 17.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Coml Physical, Biologcl Resh 0.05 -4.68 -5.10 - 16.66
Last Trade Time Trade Type Trade Size Trade Price Currency
12:57:35 O 10,000 18.3999 GBX

Genedrive (GDR) Latest News

Genedrive (GDR) Discussions and Chat

Genedrive Forums and Chat

Date Time Title Posts
08/6/202312:17Genedrive. A Game Changer for Global Covid 19 Testing Market?18,378
04/4/202317:52Genedrive (GDR) One to Watch 1,879
22/2/202222:22COVID-19 BULL FREE100
24/1/202217:07Genedrive PLC (GDR) Covid19 Diagnostics949
20/1/202210:15is share price move coming soon91

Add a New Thread

Genedrive (GDR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Genedrive (GDR) Top Chat Posts

Top Posts
Posted at 06/6/2023 15:40 by hazl
He just posts after a spike...look at the big gap here.

I believe the theory buy when it's low, however no guarantees,especially at the moment.

Only two months ago it was 40p.

JakNife - 18 Apr 2023 - 11:37:52 - 18166 of 18362 Genedrive. A Game Changer for Global Covid 19 Testing Market? - GDR
JakNife - 06 Apr 2023 - 20:50:58 - 18158 of 18362 Genedrive. A Game Changer for Global Covid 19 Testing Market? - GDR
JakNife - 04 Jun 2022 - 20:05:14 - 17147 of 18362 Genedrive. A Game Changer for Global Covid 19 Testing Market? - GDR

Posted at 11/5/2023 13:16 by fisternator
MR g2theary

Riverfort have not paid 32p a share for the £2 million prepayment facility
They have theoretically been allocated 6.5 million shares at that price to be sold to repay the £2 Million in the future.

However, if/when they (riverfort) demand repayment and sell the 6.5 million shares; if they don't received their £2 million back plus 30% then they have the right to demand more endless free shares from the company until that figure is repaid.

So the lower the better for Riverfort.

Hope this helps in your push to 30p

RNS 31 March 2023

"-- If the Investors have disposed of all the Initial Placing Shares and amounts remain outstanding, the Investors can issue subscription notices to the Company to receive further subscription shares. The subscription price payable by the Investors will be applied to reduce the amounts of the prepayment principal outstanding pursuant to the Facility. The number of shares to be issued would be calculated at the lower of the Fixed Premium Placing Price and the Adjusted Placing Price . This price is reset in the event that the Company issues further shares at a price less than the Fixed Premium Placing Price, to the lower subscription price."

"- The Initial Prepayment will be redeemed on the basis of proposed future disposals of the ordinary shares by the Investors. On service of a notice of disposal, the Facility is deemed to be redeemed by an amount equivalent to the number of ordinary shares proposed to be disposed of multiplied by the lower of (a) 130% of the relevant Reference Price for a Share (the "Fixed Premium Placing Price") and (b) an amount equivalent to an 8% discount of the selected daily VWAP in the 10 trading days prior to the service of the disposal notice (the "Adjusted Placing Price"). The Reference Price for the Initial Placing Shares is 32 pence and the Reference Price for future drawdowns will be the average of the daily VWAP for the five consecutive Trading Days prior to drawdown (Reference Price)."

Posted at 02/5/2023 13:53 by g2theary
This is what I've read-- 6,500,000 ordinary share of 1.5p each will be allotted and issued to the Investors in respect of the Initial Prepayment (the "Initial Placing Shares"). The number of ordinary shares to be issued has been calculated using a genedrive share price of 32p being the Reference Price. The shares are issued at nominal value
Posted at 18/4/2023 10:24 by sparrow9
Could be a pharmaceutical company is interested in GDR wouldn’t surprise me one bit if this is the case, the share price is a bargain I believe GDR is a must buy .
Posted at 02/4/2023 11:42 by terminator101
And this 🤡 thinks it’s “only 6.75 million shares” 🤣

Mate, those are just the shares that Riverfort use to initially sell into the market and get their £300,000 in cash. That’s then converted to even more shares at an 8% discount to the lowest share price when they sell them. And the whole thing begins agains, every month, until £2 million has been converted, and them another £3 million. Oh and Riverfort get a load of warrants too, which motivates them to drive the share price as low as they can get in order to get the best price.

David569201 Apr '23 - 16:22 - 1834 of 1850
0 0 0
The nice think about all this bickering back and forth is its only 6.75million share, less than 10% dilution thay will be shaped up with in the week.

Posted at 02/4/2023 11:37 by terminator101
The lunatics and gerbils on the LSE asylum are trying to convince themselves that the death spiral is fine 😳🤣

Don’t let the fact that there’s almost zero revenue in gdr, or that death spiral finance in every other share in the history of shares has resulted in a massive decline in the share price. WSG, NAPS, HEMO, DVRG, UKOG, AAOG, MODE, SYME, COPL, ECHO, just for recent examples.

But apparently it’s going to be different here, because those nice death spiral finance providers have shareholders best interests at heart. 😉

Even the ceo is telling you it’s going to be carnage. What exactly do people think “good liquidity” actually means? It means a healthy supply of gullible gerbils. And the only acknowledgement of shareholders from him was that its better than the alternatives, hardly a compelling sales pitch huh.

Death spiral finance even has its own wiki page it’s so awful.

Posted at 01/4/2023 08:13 by loglorry1
If I fully understand the RNS it goes as follows :

"ยท 6,500,000 ordinary share of 1.5p each will be allotted and issued to the Investors in respect of the Initial Prepayment (the "Initial Placing Shares"). The number of ordinary shares to be issued has been calculated using a genedrive share price of 32p being the Reference Price. The shares are issued at nominal value"

The initial pre-payment is £2m but 6.5m shares at 32p is £2.08m which is close to £2m but then it goes on to say "The shares are issued at nominal value" which is 1.5p as I explain below the 32p or 1.5p here is not relevant.

The RNS then goes on to say :

"The Initial Prepayment will be redeemed on the basis of proposed future disposals of the ordinary shares by the Investors. "

So this describes how the investor get's their money back (basically by selling the shares into the market at a VWAP discount or 130% of 32p whichever is lower).

So this suggests that the 32p "paid for" the initial payment is totally irrelevant because GDR are really paying off the £2m at VWAP - 8% (or 130% x 35p if higher).

After a redemption the reference price resets to average 5 day VWAP prior to drawdown (bascially lowering or raisng the cap). So for example if there is a period of low prices say 25p prior to conversion then the new reference price will be 25p.

In addition the investor gets 40% of draw down in warrants with strike equal to 140% of the reference price e.g. 140% * 25p in my example. It's 44.8p strike intially but dont' forget the refernece price resets afrer the conversions so I think this is lowered.

As a final kicker for the investor they get 2% of the £5m = £100K plus 4% on the pre-payment (£2m I think) which is a further £80K which they are electing to pay as 250K shares that's 32p/shr.

There is a limit to how fast the investor can convert the additional £3m on similar terms to be £300/month.

So what this all seems to mean is that if the investor gets the share price lower to around 20p for even a single day during a 20 day period prior to conversion then they can convert at VWAP-8% for these shares causing a lot of dilution and then also reset the reference price much lower and get a lot of cheap warrants.

It's a fantastic deal for Riverfort they can't loose. It is not too bad for shareholders as long as the share price can be held up (private investors keep bidding it up). If the share price is not held up then it will quickly spiral down as higher number of shares increase dramatically via the conversions.

Remember at 32p the market cap is c£25m. If the conversions take place even at 25p we are looking at significant dilution here and it's unclear if private investors can absorb this many shares hitting the tape.

Posted at 30/3/2023 21:19 by bones698
Coscos it's not a good thing if it's dillutive . At the end of the day the more shares issues at lower prices the less the gains will be if they get there .

If you can't u deratand simple maths of dillution V reward then your in the wrong game .

Many companies have failed to raise cash or generate such dillution the shares become almost irrelevant as there are so many . It's a fine balancing act and if there y can raise now y at higher share prices then it works but if the shareprice falls and they need cash it's Not good . Biotech and pharma companies in the uk have always struggled to raise money especially in the later stages and no matter howgood the news is a long fhe way .

Be warned this will be a bumpy ride at least it's heading in the right direction now after years of decline so hope it continues and they raise cash at a good price
If there's a spike on FDA approval assuming they get it I'd say sell and wait as this is no guarantee of success either ,look at agl for some lessons

Posted at 30/3/2023 12:33 by coscos
I'm tired of reading about the cash they need raise. How do you think a company grows if it doesn't have the cash it needs? Difference now is that they have a solid product with which to progress the company growth, it's not wishful thinking anymore

Any cash raise will be a GOOD thing and POSITIVE for the share price as GDR will now start growing through contracts and sales, not just for burning through as before.

Personally I would be pleased to see a cash raise (if they need to, I think there are other means they can turn to aswell - venture capitalists etc)because it means they are going for growth.

Where do you think the share price will be when further agreements are signed all over the world during the next few years? Any FDA news on this will make the current share price look very silly indeed. Exciting times ahead here.

Posted at 27/1/2023 13:14 by indomie1
As others have said this rise really feels like it is due to a long awaited re-rate as stock was heavily oversold on little or no news. I'm not sure the market appreciated the significance of the NICE decision to prioritise the assessment of GDRs two pharmacogenomic tests either before xmas.

It has always been a difficult share to judge as it wasn't clear with the pandemic whether GDRs strategy - which relies on healthcare systems around the world prioritising genomics to help manage demand, reduce costs and improve patient outcomes - would be adopted. IMO it is now starting to look like with the extra pressures on health systems following the pandemic, that genomics WILL be a big winner in terms of new research, innovation and products.

GDR has been ahead of others in this market. The decision by the company to pivot to using their technology to try to help during the pandemic, has helped to fund upgrades to their diagnostic platforms, and now the delays in regulatory approval caused by the pandemic only seem to have accelerated interest in pharmacogenomic testing in a way that was probably not envisaged pre-pandemic.

There are still very real ethical issues to work through with areas like genomic sequencing, but if health care providers are working towards the adoption of that technology, then they need widespread adoption/acceptance of the sort of tests GDR are now bringing to market which do not have as significant ethical issues.

As others have said, do your own research here. Some may not believe pharmacogencomic testing will take off, others can see a real patient need and GDR as a 200-300m market cap business in a reasonable timeframe.

GDR have never provided any detailed breakdown on the global market for their AIHL test, other than saying it is in excess of 100m in annual sales - the focus was initially on UK, Europe and USA but now with entry to the Middle East market, there are clear signs the company is seeing interest further afield too. The stroke test has even bigger potential uses, and the reputation and experience GDR have built up have positioned the firm well. Some things are outside of their control - national NHS commissioning of the AIHL test would transform this company and any valuations - but that decision is outside of GDRs control. In the meantime, they are focusing on getting a NICE recommendation which will help take up with all the trusts they are currently in discussions. The company is also due to update on their strategy to enter the US/North American market, and launch its stroke test, so lots of news still to come in 2023!


Genedrive share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230608 12:16:35